On Friday, the U.S. Food and Drug Administration (FDA) approved Cytokinetics Incorporated’s (NASDAQ:CYTK) Myqorzo (aficamten) for symptomatic obstructive hypertrophic cardiomyopathy (oHCM) to improve functional capacity and symptoms.Myqorzo is an allosteric and reversible inhibitor of cardiac myosin motor activity. In patients with oHCM, myosin inhibition with Myqorzo reduces cardiac contractility and left ventricular outflow tract (LVOT) obstruction.The full U.S. Prescribing Information for Myqorzo include ...